We are a pure-play in vitro diagnostics (“IVD”) business driven by our credo, “Because Every Test is A Life.” 

Our solutions are central to the operations of hospitals, clinics, blood banks and donor centers around the world, where they are used to help diagnose certain conditions, such as cancer or heart attacks, and infectious diseases, such as hepatitis, HIV, and most recently, COVID-19, where we have launched two antibody tests and an antigen test, and we are actively expanding our menu of tests to address the global pandemic.

The U.S. Food and Drug Administration granted the company Emergency Use Authorization approvals in April 2020 for its COVID-19 antibody and antigen tests.

We have been pioneering life-impacting advances in diagnostics for over 80 years, from our earliest work in blood typing, to our innovation in infectious diseases and our latest developments in laboratory solutions. In 2014, we were acquired by The Carlyle Group from Johnson & Johnson and became an independent organization, solely focused on delivering high quality IVD products and service to our diagnostic customer base. At the time of the separation, our business had global scale, a reputation for high quality products, a strong quality management system and a research and development team with extensive scientific expertise,

 (Note: Ortho Clinical Diagnostics priced its IPO on Jan. 27, 2021, at $17 – below its $20-to-$23 range – and more shares – 76 million shares, up from 70 million shares in its prospectus – to raise $1,292.0 million ($1.292 billion).